Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Zackery P. Bulman

Zackery P. Bulman


Assistant Professor, College of Pharmacy - Pharmacy Practice
Director, Infectious Diseases Pharmacology Fellowship, Pharmacy Practice

Contact

Office Phone:

(312) 996-1415 (work)

About Heading link

Research Interests:
The medical community is at a constant state of war with bacteria to both prevent and overcome antimicrobial resistance, which is one of the largest threats to global health. The frequency and nature of bacterial cell replication combined with the widespread use of antibiotics suggests that antimicrobial resistance is likely to persist. Dr. Bulman’s laboratory investigates novel pharmacotherapeutic approaches that aim to overcome drug resistant bacteria and improve patient outcomes.

Teaching and Supervision Heading link

Undergrad Resrch Pharm Pract (PMPR 380), 1/8/2024 – 4/26/2024
Applied Research Methods (PMPR 376), 1/8/2024 – 4/26/2024
Undergrad Resrch Pharm Pract (PMPR 380), 8/21/2023 – 12/1/2023
Applied Research Methods (PMPR 376), 1/9/2023 – 4/28/2023
Pathophysiology, Drug Action, & Therapeutics (PDAT) 6: Infectious Diseases (PHAR 506), 1/1/2023 – 5/1/2023
Undergrad Resrch Pharm Pract (PMPR 380), 8/22/2022 – 12/2/2022
Pharmacokinetics (PHAR 435), 8/22/2022 – 12/2/2022
Pharmacokinetics (PHAR 435), 8/22/2022 – 12/2/2022
Undergrad Resrch Pharm Pract (PMPR 380), 1/10/2022 – 4/29/2022

Selected Grants

Maribavir Clearance during in vitro Continuous Renal Replacement Therapy, Takeda Pharmaceuticals., 12/12/2023 - 6/1/2025, Obligated Amount: $146513.18; Anticipated Amount: $146513.18

Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae, National Institutes of Health (National Institute of Allergy and Infectious Diseases)., 12/5/2022 - 11/30/2027, Obligated Amount: $1439905; Anticipated Amount: $3660946

Selected Publications

Shin, Eunjeong, Zhang, Yongzhen, Zhou, Jieqiang, Lang, Yinzhi, Sayed, Alaa RM, Werkman, Carolin, Jiao, Yuanyuan, Kumaraswamy, Monika, Bulman, Zackery P, Luna, Brian M, Bulitta, Jürgen B. (2024). Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics.. Antimicrobial Agents and Chemotherapy, 68, (2), e0139323. doi:10.1128/aac.01393-23.

Andrianopoulou, Angeliki, Sokolowski, Karol, Wenzler, Eric, Bulman, Zackery P, Gemeinhart, Richard A. (2024). Assessment of antibiotic release and antibacterial efficacy from pendant glutathione hydrogels using ex vivo porcine skin. Journal of Controlled Release, 365, 936-949. doi:10.1016/j.jconrel.2023.12.008.

Palmer, Mary E, Belcher, Rachel M, Engeleit, Anastasia, Wenzler, Eric, Bulman, Zackery P, Benken, Scott T. (2023). Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19. International Journal of Antimicrobial Agents, 62, (3), 106920. doi:10.1016/j.ijantimicag.2023.106920.

Bulman, Zackery P, Wicha, Sebastian G, Nielsen, Elisabet I, Lenhard, Justin R, Nation, Roger L, Theuretzbacher, Ursula, Derendorf, Hartmut, Tängdén, Thomas, Zeitlinger, Markus, Landersdorfer, Cornelia B, Bulitta, Jürgen B, Friberg, Lena E, Li, Jian, Tsuji, Brian T, Pharmacology, International Society of Anti-Infective, Group, European Society of Clinical Microbiology and Infectious Diseases Pharmacokinetics and Pharmacodynamics of Anti-Infectives Study, Group, International Society of Antimicrobial Chemotherapy Anti-Infective Pharmacology Working. (2022). Research priorities towards precision antibiotic therapy to improve patient care. The Lancet Microbe, 3, (10), e795-e802. doi:10.1016/s2666-5247(22)00121-5.

Smith, Nicholas M, Boissonneault, Katie Rose, Chen, Liang, Petraitis, Vidmantas, Petraitiene, Ruta, Tao, Xun, Zhou, Jieqiang, Lang, Yinzhi, Kavaliauskas, Povilas, Bulman, Zackery P, Holden, Patricia N, Cha, Raymond, Bulitta, Jürgen B, Kreiswirth, Barry N, Walsh, Thomas J, Tsuji, Brian T. (2022). Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity. Antimicrobial Agents and Chemotherapy, 66, (9), e00527-e00522. doi:10.1128/aac.00527-22.

Singh, Nidhi, Poggensee, Linda, Huang, Yanqin, Evans, Charlesnika T, Suda, Katie J, Bulman, Zackery P. (2022). Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020. JAC-Antimicrobial Resistance, 4, (3), dlac049. doi:10.1093/jacamr/dlac049.

Huang, Yanqin, Rana, Amisha P, Wenzler, Eric, Ozer, Egon A, Krapp, Fiorella, Bulitta, Jürgen B, Hauser, Alan R, Bulman, Zackery P. (2022). Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 77, (2), 356-363. doi:10.1093/jac/dkab381.

Bulman, Zackery P, Tan, Xing, Chu, Ting-Yu, Huang, Yanqin, Rana, Amisha P, Singh, Nidhi, Flowers, Stephanie A, Kyono, Yasuhiro, Kreiswirth, Barry N, Chen, Liang. (2022). Ceftazidime-avibactam based combinations against carbapenemase producing Klebsiella pneumoniae harboring hypervirulence plasmids. Computational and Structural Biotechnology Journal, 20, 3946-3954. doi:10.1016/j.csbj.2022.07.017.

Bulman, Zackery P, Krapp, Fiorella, Pincus, Nathan B, Wenzler, Eric, Murphy, Katherine R, Qi, Chao, Ozer, Egon A, Hauser, Alan R. (2021). Genomic Features Associated with the Degree of Phenotypic Resistance to Carbapenems in Carbapenem-Resistant Klebsiella pneumoniae. mSystems, 6, (5), e00194-e00121. doi:10.1128/msystems.00194-21.

Professional Leadership

SIDP Website Committee, Society for Infectious Diseases Pharmacists, 11/1/2022 - 10/31/2023

ISAC Anti-Infective Pharmacology Working Group, 12/2/2019 - Present

ISAP Treasurer, International Society of Anti-Infective Pharmacology, 2018 - Present

Notable Honors

2023, UIC Researcher of the Year- Rising Star Award in Clinical Sciences, University of Illinois at Chicago

2020, FISAC, International Society of Antimicrobial Chemotherapy

2020, Hans W. Vahlteich Research Scholar,

Education

Degrees:
PharmD, University at Buffalo, State University of New York, United States, 2015
B.S., Rochester Institute of Technology, United States, 2011

Postgraduate Training:
Infectious Diseases Pharmacology Fellowship, University at Buffalo, State University of New York, United States, 2017
Clinical and Translational Research Fellow, VA Western New York Healthcare System, United States, 2017

Selected Presentations

Bulman, Zackery. (2021 December 17). Genotype specific combination treatment strategies to thwart KPC-producing K. pneumoniae. Antimicrobial Resistance Symposium. Beijing, China [Virtual Seminar].